ESSA Pharma (NASDAQ:EPIX) Stock Crosses Below Fifty Day Moving Average of $8.25

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI)’s share price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $8.25 and traded as low as $5.71. ESSA Pharma shares last traded at $6.08, with a volume of 178,467 shares changing hands.

ESSA Pharma Price Performance

The company has a 50 day moving average of $8.25 and a 200 day moving average of $7.11.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last announced its quarterly earnings results on Tuesday, February 13th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. Equities analysts predict that ESSA Pharma Inc. will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On ESSA Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. RTW Investments LP acquired a new stake in ESSA Pharma during the fourth quarter worth about $15,171,000. Rock Springs Capital Management LP increased its stake in ESSA Pharma by 2.1% during the third quarter. Rock Springs Capital Management LP now owns 677,005 shares of the company’s stock worth $2,092,000 after acquiring an additional 13,688 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in ESSA Pharma by 164.9% during the fourth quarter. BNP Paribas Financial Markets now owns 57,466 shares of the company’s stock worth $379,000 after acquiring an additional 35,771 shares during the last quarter. 75.12% of the stock is currently owned by institutional investors and hedge funds.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.